Search - tctmd.com

Displaying 61 - 80 of 227

Sort: Relevancy | Date

Presentation TCT 2015

DCBs Plus Adjunctive BMS Use: Current Use, Rationale, and Pitfalls

Presenter: Krishna J. Rocha-Singh, Andrej Schmidt

October 12, 2015

Presentation TCT 2015

Next-Generation DCBs: Alternative Coatings and Drug-Delivery Platforms for SFA Intervention

Presenter: Krishna J. Rocha-Singh, Andrej Schmidt, Juan F. Granada

October 12, 2015

Presentation TCT 2015

12 Month Outcomes From the Lutonix Global SFA Real-World Registry

Presenter: John R. Laird Jr, Gunnar Tepe, Marcus Thieme

October 12, 2015

Presentation TCT 2015

The IN.PACT Global Registry: One-Year Outcomes Using the IN.PACT DCB in an Unrestricted, Real-World Environment

Presenter: John R. Laird Jr, Gunnar Tepe, Gary M. Ansel

October 12, 2015

Presentation TCT 2015

DCB for Long and Highly Calcified Vessels: Is Upfront Vessel Preparation a Rational Choice?

Presenter: John R. Laird Jr, Gunnar Tepe

October 12, 2015

Presentation TCT 2015

DCB Treatment of In-Stent Restenosis With or Without Upfront Debulking: Updated Results

Presenter: John R. Laird Jr, Gunnar Tepe, Thomas Zeller

October 12, 2015

Presentation TCT 2015

The ILLUMINATE RCT: One-Year Outcomes

Presenter: William A. Gray, Peter A. Schneider, Mahmood K. Razavi

October 12, 2015

Presentation TCT 2015

Extended Follow-up From LEVANT 2: Two-Year Follow-up and Subgroup Analyses

Presenter: William A. Gray, Peter A. Schneider, Andrej Schmidt

October 12, 2015

Presentation TCT 2015

IN.PACT SFA 1-year Outcomes: Subgroup Analyses

Presenter: William A. Gray, Peter A. Schneider, John R. Laird Jr

October 12, 2015

Presentation TCT 2015

Optimizing Outcomes With DCB: Tips and Tricks

Presenter: Greg L. Kaluza, Thomas Zeller

October 12, 2015

Presentation TCT 2015

FIH Data Review Regarding Degree and Duration of DCB Efficacy in De Novo Lesions: Is There a Class Effect?

Presenter: Greg L. Kaluza, Thomas Zeller, Gunnar Tepe

October 12, 2015

Presentation TCT 2015

Technical Overview of FDA-Approved and CE-Marked DCB Technologies for PVD Intervention

Presenter: Greg L. Kaluza, Thomas Zeller

October 12, 2015

News Conference News TCT 2015

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

October 12, 2015

News Industry News

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

October 07, 2015

News Industry News

QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch

October 06, 2015

News Industry News

Intact Vascular Announces Conditional FDA Approval for Tack Optimized Balloon Angioplasty II (TOBA II) Study and Enrollment of First Patients

September 30, 2015

News Industry News

QT Vascular wins CE Mark for drug-coated balloon

September 10, 2015

News Industry News

Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex(TM) Drug-Coated Balloon Technology

July 29, 2015

News Industry News

QT Vascular Announces The Allowance Of Four New Patents

July 15, 2015

News Daily News

RIBS IV: Los SLE Superan a los BRF en el Manejo de la Reestenosis Intra-Stent

L.A. McKeown

July 01, 2015

Advertisement

DCBs Plus Adjunctive BMS Use: Current Use, Rationale, and Pitfalls

Next-Generation DCBs: Alternative Coatings and Drug-Delivery Platforms for SFA Intervention

12 Month Outcomes From the Lutonix Global SFA Real-World Registry

The IN.PACT Global Registry: One-Year Outcomes Using the IN.PACT DCB in an Unrestricted, Real-World Environment

DCB for Long and Highly Calcified Vessels: Is Upfront Vessel Preparation a Rational Choice?

DCB Treatment of In-Stent Restenosis With or Without Upfront Debulking: Updated Results

The ILLUMINATE RCT: One-Year Outcomes

Extended Follow-up From LEVANT 2: Two-Year Follow-up and Subgroup Analyses

IN.PACT SFA 1-year Outcomes: Subgroup Analyses

Optimizing Outcomes With DCB: Tips and Tricks

FIH Data Review Regarding Degree and Duration of DCB Efficacy in De Novo Lesions: Is There a Class Effect?

Technical Overview of FDA-Approved and CE-Marked DCB Technologies for PVD Intervention

Boston Scientific Co-founder John Abele Recognized by TCT Career Achievement Award

Medtronic to Unveil New Clinical Data for its Innovative Portfolio of Interventional Technologies at TCT 2015

QT Vascular Announces Interim Clinical Trial Results Of Chocolate Touch

Intact Vascular Announces Conditional FDA Approval for Tack Optimized Balloon Angioplasty II (TOBA II) Study and Enrollment of First Patients

QT Vascular wins CE Mark for drug-coated balloon

Spectranetics Completes Enrollment in ILLUMENATE Pivotal Study to Assess Safety and Efficacy of Stellarex(TM) Drug-Coated Balloon Technology

QT Vascular Announces The Allowance Of Four New Patents

RIBS IV: Los SLE Superan a los BRF en el Manejo de la Reestenosis Intra-Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content